Evidence Hub

Pseudomonas aeruginosa in patients with Nosocomial Respiratory Infections: A secondary analysis of the European Network for ICU-Related Respiratory Infections (ENIRRIs)

Cristian C. Serrano-Mayorga, Juan Olivella-Gómez, Natalia Sanabria-Herrera, S. Nseir, A. Torres, I. Martín-Loeches, L. F. Reyes

Chest, 2026

1,059 participants · 4 citations

Abstract

BACKGROUND

Nosocomial respiratory infections (NRIs) are the most common complication among ICU patients, with Pseudomonas aeruginosa frequently identified. However, its global prevalence and associated risk factors remain unclear.

RESEARCH QUESTION

Among ICU patients with NRI, what is the international prevalence of P. aeruginosa, and which clinical factors are associated with an increased risk?

STUDY DESIGN AND METHODS

This secondary analysis used data from the European Network for ICU-Related Respiratory Infections (ENIRRI), a prospective cohort study conducted across 12 countries from May 2016 to August 2019. Data from 1,059 NRI patients who underwent microbiological testing were analyzed. Descriptive statistics, imputation of missing data, LASSO regression, Elastic Net, Random Forest, and multivariable logistic regression were applied. Model performance was assessed using McFadden's R2 and the Hosmer-Lemeshow test.

RESULTS

The median patient age was 64 years (IQR 49-73), and 72% were male. Pathogens were identified in 67% (710/1059) of cases, primarily using blood cultures (78%). P. aeruginosa was detected in 14.5% (n=153), with antimicrobial resistance mechanisms in 5.1% (n=55). Among these, 19.6% were multidrug-resistant and 11.1% produced carbapenemase. The highest prevalence was observed in Germany, Argentina, and France. Ventilator-associated pneumonia (VAP) was the predominant diagnosis, accounting for 66% of P. aeruginosa cases. Septic shock and acute kidney…

How strong is the evidence?

Evidence Hub reads this as a secondary / pooled analysis, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,059 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free